Place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitus

Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, known as statins, have revolutionized the treatment of hypercholesterolemia and coronary artery disease prevention. However, there are considerable issues regarding statin safety and further development of residual risk control, particularly for diabetic and metabolic syndrome patients. Pitavastatin is a potent statin with low-density lipoprotein (LDL) cholesterol-lowering effects comparable to those of atorvastatin or rosuvastatin. Pitavastatin has a high-density lipoprotein (HDL) cholesterol raising effect, may improve insulin resistance, and has little influence on glucose metabolism. Considering these factors along with its unique pharmacokinetic properties, which suggest minimal drug–drug interaction, pitavastatin could provide an alternative treatment choice, especially in patients with glucose intolerance or diabetes mellitus. Many clinical trials are now underway to test the clinical efficacy of pitavastatin in various settings and are expected to provide further information.

• Publication year

  2011

• Venue

  Drug Design, Development and Therapy

• Publication date

  2011-05-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.2147/DDDT.S13492PMID 21625418PMCID 3100224
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• United Kingdom Prospective Diabetes Study (UKPDS)

  2020cited by this paper
• The drug efficacy and adverse reactions in a mouse model of oral squamous cell carcinoma treated with oxaliplatin at different time points during a day

  2013cited by this paper
• Rationale and design of a study to evaluate effects of pitavastatin on Japanese patients with chronic heart failure: the pitavastatin heart failure study (PEARL study).

  2012cited by this paper
• Drug‐Drug Interaction Study to Assess the Effects of Multiple‐Dose Pitavastatin on Steady‐State Warfarin in Healthy Adult Volunteers

  2011influential reference
• Nanoparticle-Mediated Delivery of Pitavastatin Into Lungs Ameliorates the Development and Induces Regression of Monocrotaline-Induced Pulmonary Artery Hypertension

  2011cited by this paper
• Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

  2011cited by this paper
• Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

  2010cited by this paper
• Nanoparticle-mediated endothelial cell-selective delivery of pitavastatin induces functional collateral arteries (therapeutic arteriogenesis) in a rabbit model of chronic hind limb ischemia.

  2010cited by this paper
• Effects of pitavastatin (LIVALO tablet) on the estimated glomerular filtration rate (eGFR) in hypercholesterolemic patients with chronic kidney disease. Sub-analysis of the LIVALO Effectiveness and Safety (LIVES) Study.

  2010cited by this paper
• ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY GROUP. EFFECTS OF INTENSIVE GLUCOSE LOWERING IN TYPE 2 DIABETES

  2010cited by this paper
• Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia.

  2010cited by this paper
• Beneficial direct adipotropic actions of pitavastatin in vitro and their manifestations in obese mice.

  2010cited by this paper
• Pitavastatin Reduces Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Ligands in Hypercholesterolemic Humans

  2010cited by this paper
• Diabetes mellitus is a major negative determinant of coronary plaque regression during statin therapy in patients with acute coronary syndrome--serial intravascular ultrasound observations from the Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome Trial (the JAPAN-ACS Tria

  2010cited by this paper
• Pitavastatin - pharmacological profile from early phase studies.

  2010cited by this paper
• [Japan Diabetes Complications Study (JDCS)].

  2010cited by this paper
• Stabilization and regression of coronary plaques treated with pitavastatin proven by angioscopy and intravascular ultrasound--the TOGETHAR trial.

  2010cited by this paper
• Induction of Endothelial Nitric Oxide Synthase, SIRT1, and Catalase by Statins Inhibits Endothelial Senescence Through the Akt Pathway

  2010cited by this paper
• Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.

  2010cited by this paper
• New evidence on pitavastatin: efficacy and safety in clinical studies

  2010cited by this paper
• Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis.

  2010cited by this paper
• More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome--sub-analysis of JAPAN-ACS study.

  2010cited by this paper
• [Japan Diabetes Complications Study (JDCS)].

  2010cited by this paper
• High-Density Lipoprotein Modulates Glucose Metabolism in Patients With Type 2 Diabetes Mellitus

  2009cited by this paper
• The SLCO1B1*5 genetic variant is associated with statin-induced side effects.

  2009cited by this paper
• Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia

  2009cited by this paper
• Endothelial Dysfunction as a Target for Prevention of Cardiovascular Disease

  2009cited by this paper
• SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation.

  2009cited by this paper
• Effects of pitavastatin (LIVALO Tablet) on high density lipoprotein cholesterol (HDL-C) in hypercholesterolemia.

  2009cited by this paper
• Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.

  2009cited by this paper
• Integrative Physiology/Experimental Medicine Therapeutic Neovascularization by Nanotechnology- Mediated Cell-Selective Delivery of Pitavastatin Into the Vascular Endothelium

  2009cited by this paper
• Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia

  2009cited by this paper
• Effects of Intensive Glucose Lowering in Type 2 Diabetes

  2009cited by this paper
• Early effect of lipid-lowering therapy with pitavastatin on regression of coronary atherosclerotic plaque. Comparison with atorvastatin.

  2009cited by this paper
• An update on the lipid nephrotoxicity hypothesis

  2009cited by this paper
• Rosuvastatin in older patients with systolic heart failure.

  2009cited by this paper
• Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals

  2009cited by this paper
• Effects of pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardio-ankle vascular index in type 2 diabetic patients.

  2009cited by this paper
• Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis

  2009cited by this paper
• Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin

  2009cited by this paper
• Influence of statins on glucose tolerance in patients with type 2 diabetes mellitus: subanalysis of the collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study).

  2009influential reference
• Management of non-high-density lipoprotein abnormalities.

  2009influential reference
• Beneficial effects of pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardiac function in ischemic and nonischemic heart failure.

  2008cited by this paper
• High-Sensitivity C-Reactive Protein and Coronary Heart Disease in a General Population of Japanese: The Hisayama Study

  2008cited by this paper
• Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

  2008cited by this paper
• Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation.

  2008cited by this paper
• Atorvastatin-induced changes in plasma coenzyme q10 and brain natriuretic peptide in patients with coronary artery disease.

  2008cited by this paper
• Effect of a multifactorial intervention on mortality in type 2 diabetes.

  2008cited by this paper
• Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus.

  2008cited by this paper
• Proposed guidelines for hypertriglyceridemia in Japan with non-HDL cholesterol as the second target.

  2008cited by this paper
• Effects of pitavastatin on lipid profiles and high-sensitivity CRP in Japanese subjects with hypercholesterolemia: Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) investigatars.

  2008cited by this paper
• Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials.

  2008cited by this paper
• Comparison of Effects of Pitavastatin and Atorvastatin on Plasma Coenzyme Q10 in Heterozygous Familial Hypercholesterolemia: Results From a Crossover Study

  2008cited by this paper
• SLCO1B1 variants and statin-induced myopathy--a genomewide study.

  2008cited by this paper
• Combined Effects of an 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor and Angiotensin II Receptor Antagonist on Nitric Oxide Bioavailability and Atherosclerotic Change in Myocardial Infarction-Prone Watanabe Heritable Hyperlipidemic Rabbits

  2008cited by this paper
• Pitavastatin decreases plasma prebeta1-HDL concentration and might promote its disappearance rate in hypercholesterolemic patients.

  2008cited by this paper
• Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3T3L1 adipocytes.

  2008cited by this paper
• Correlation between adiponectin and reduction of cell adhesion molecules after pitavastatin treatment in hyperlipidemic patients with type 2 diabetes mellitus.

  2008cited by this paper
• Rapid Stabilization of Vulnerable Carotid Plaque Within 1 Month of Pitavastatin Treatment in Patients With Acute Coronary Syndrome

  2008cited by this paper
• Coenzyme Q10: an independent predictor of mortality in chronic heart failure.

  2008cited by this paper
• Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.

  2008cited by this paper
• A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance

  2008cited by this paper
• Comparisons of short- and intermediate-term effects of pitavastatin versus atorvastatin on lipid profiles, fibrinolytic parameter, and endothelial function.

  2008cited by this paper
• A Large-scale, Long-term, Prospective Post-marketing Surveillance of Pitavastatin (LIVALO®Tablet) : LIVALO Effectiveness and Safety (LIVES) Study

  2008cited by this paper
• Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.

  2008cited by this paper
• Effects of intensive glucose lowering in type 2 diabetes.

  2008cited by this paper
• Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

  2008cited by this paper
• Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study).

  2008influential reference
• Rosuvastatin in older patients with systolic heart failure.

  2007cited by this paper
• The effects of statin and fibrate on lowering small dense LDL- cholesterol in hyperlipidemic patients with type 2 diabetes.

  2007cited by this paper
• Endothelial dysfunction in diabetes mellitus

  2007cited by this paper
• Diagnostic criteria for dyslipidemia. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese.

  2007cited by this paper
• Plaque characterisation by Virtual Histology intravascular ultrasound analysis in patients with type 2 diabetes

  2007cited by this paper
• Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese.

  2007cited by this paper
• Risk of coronary events in Japanese patients with both hypercholesterolemia and type 2 diabetes mellitus on low-dose simvastatin therapy: implication from Japan Lipid Intervention Trial (J-LIT).

  2007cited by this paper
• Renal protective effects of pitavastatin on spontaneously hypercholesterolaemic Imai Rats.

  2007cited by this paper
• Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients§

  2007cited by this paper
• Serial Metabolic Measurements and Conversion to Type 2 Diabetes in the West of Scotland Coronary Prevention Study

  2007cited by this paper
• Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy.

  2006cited by this paper
• C-Reactive Protein Levels and Outcomes After Statin Therapy

  2006cited by this paper
• Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control

  2006cited by this paper
• Pitavastatin

  2005cited by this paper
• Effect of pitavastatin on transactivation of human serum paraoxonase 1 gene.

  2005cited by this paper
• C-reactive protein levels and outcomes after statin therapy.

  2005cited by this paper
• Elevated C-reactive protein is a predictor of the development of diabetes in a general Japanese population: the Hisayama Study.

  2005cited by this paper
• Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.

  2005cited by this paper
• Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy.

  2005cited by this paper
• Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin.

  2005cited by this paper
• A systematic review of drug therapy to delay or prevent type 2 diabetes.

  2005cited by this paper
• Echolucent carotid plaques predict future coronary events in patients with coronary artery disease.

  2004cited by this paper
• Relationship Between Cardiovascular Risk as Predicted by Established Risk Scores Versus Plaque Progression as Measured by Serial Intravascular Ultrasound in Left Main Coronary Arteries

  2004cited by this paper
• Clinical Significance of Small Dense Low-Density Lipoprotein Cholesterol Levels Determined by the Simple Precipitation Method

  2004cited by this paper
• Pitavastatin increases ABCA1-mediated lipid efflux from Fu5AH rat hepatoma cells.

  2004cited by this paper
• Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell.

  2004cited by this paper
• [Pharmacological and pharmacokinetic features and clinical effects of pitavastatin (Livalo Tablet)].

  2004cited by this paper
• 新規HMG-CoA還元酵素阻害薬ピタバスタチン（リバロ錠®）の薬理および薬物動態的特徴と臨床効果

  2004cited by this paper
• Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.

  2003cited by this paper
• Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study.

  2003cited by this paper
• Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes.

  2003cited by this paper
• C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study.

  2002cited by this paper

• Comparative Effectiveness of Pitavastatin Versus Atorvastatin on Lipid Profile and Blood Sugar in Patients of Diabetic Dyslipidemia: An Open-Label Comparative Study

  2025cites this paper
• Long-term outcomes of statin dose, class, and use intensity on primary prevention of cardiovascular mortality: a national T2DM cohort study

  2023cites this paper
• RSSDI consensus recommendations for dyslipidemia management in diabetes mellitus

  2022cites this paper
• Hypoglycemic and hypolipidemic effects of Corchorus olitorius leaves as a food supplement on rats with alloxan-induced diabet

  2020influential citation
• Statins and diabetes: focus on pitavastatin

  2020cites this paper
• New Aspects of Cellular Cholesterol Regulation on Blood Glucose Control—Review and Perspective on the Impact of Statin Medications on Metabolic Health

  2017cites this paper
• Viejos y nuevos hipolipemiantes

  2016cites this paper
• Clinical benefits of pitavastatin: focus on patients with diabetes or at risk of developing diabetes.

  2016cites this paper
• Anti-Inflammatory Effects of Atorvastatin by the Modulation of NF-κB Expression during Hyperglycemia-Induced Nephropathy in Rat

  2016cites this paper
• Different effects of statins on induction of diabetes mellitus: an experimental study

  2015cites this paper
• Use of statins and the incidence of type 2 diabetes mellitus.

  2015cites this paper
• Different effects of statins on induction of diabetes mellitus: an experimental study

  2015cites this paper
• Statin Lactonization by Uridine 5'-Diphospho-glucuronosyltransferases (UGTs).

  2015cites this paper
• RENOPROTECTIVE EFFECT OF OCIMUM SANCTUM IN COMPARISON WITH OLMESARTAN MEDOXOMIL AND PITAVASTATIN IN METFORMIN TREATED DIABETIC RATS

  2015cites this paper
• Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin.

  2015cites this paper
• New-onset diabetes and statins: throw the bath water out, but, please, keep the baby!

  2015cites this paper
• [Statins diabetogenicity: are all the same? state of art].

  2015cites this paper
• Statin use and risk of diabetes mellitus.

  2015cites this paper
• The INTREPID Phase IV Trial — Mean Percent Change in Low-density Lipoprotein Cholesterol from Baseline to Week 12

  2014cites this paper
• Are hypertriglyceridemia and low HDL causal factors in the development of insulin resistance?

  2014cites this paper
• Statin-associated incident diabetes: a literature review.

  2014cites this paper
• The Influence of statins on glucose tolerance and incipient diabetes

  2014cites this paper
• Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin

  2014cites this paper
• Effect of Pitavastatin on Vascular Reactivity in Hypercholesterolemic Rabbits

  2014cites this paper
• Pathogenesis and Management of the Diabetogenic Effect of Statins: a Role for Adiponectin and Coenzyme Q10?

  2014cites this paper
• Administration of Angiotensin Receptor II Blockade Improves Vascular Function, Urinary Albumin Excretion, and Left Ventricular Hypertrophy in Low-Risk Essential Hypertensive Patients Receiving Antihypertensive Treatment with Calcium Channel Blockers

  2013influential citation
• Searching the place of pitavastatin in the current treatment of patients with dyslipidemia

  2013cites this paper
• Individualizing Statin Therapy

  2013cites this paper
• Novel mechanisms for prevention and treatment of type 2 diabetes

  2013cites this paper
• Addressing key questions with statin therapy.

  2012cites this paper
• Meeting new challenges with antiplatelet therapy in primary care.

  2012cites this paper
• Lovastatin inhibits proliferation of anaplastic thyroid cancer cells through up-regulation of p27 by interfering with the Rho/ROCK-mediated pathway.

  2011cites this paper